Results 111 to 120 of about 30,618 (276)

Pharmacogenetics of Efavirenz response in Bantu-speaking South African HIV/AIDS patients

, 2011
Includes abstract.Includes bibliographical references (leaves 82-96).Efavirenz (EFV) is used in first-line antiretroviral (ARV) therapy of HIV-infected patients, and is principally metabolised by CYP1A2, CYP2A6, CYP2B6, CYP3A4/5 and the drug transporter ...
Swart, Marelize
core  

Pharmacovigilance, pharmacogenetics and poisoning

, 2017
CONTENTS \ud \ud 5.1 Pharmacovigilance \ud \ud - 5.1.1 Adverse drug effects \ud \ud 5.1.1.1 Types \ud \ud 5.1.1.2 Monitoring of adverse effects \ud \ud - 5.1.2 Adverse drug interactions \ud \ud 5.2.1.1 Pharmacokinetic \ud \ud 5 ...
Doggrell, Sheila
core  

UGT1A1 Fragment Analysis: Genotyping the (TA)n Variable Repeat Polymorphism for Clinical Applications

Journal of Clinical Laboratory Analysis, EarlyView.
This study developed a PCR‐based fragment analysis assay for UGT1A1 rs3064744 targeting TA5 (*36), TA6 (*1), TA7 (*28), and TA8 (*37). The assay was CLIA validated with data showing 100% concordance and a sensitivity of 0.5 ng/uL. The assay was then implemented in a patient cohort of n = 940 and the results compared with PharmacoScan.
Ryan N. Baugher, Kristen M. Pike, Teri M. Plona, Stephanie D. Mellott, Todd B. Young, Heidi E. Lawhorn, Stephen M. Hewitt   +6 more
wiley   +1 more source

Biological and prognostic relevance of A-to-I RNA editing across consensus molecular subtypes of colon cancer

Scientific Reports
Colorectal cancer (CRC) is the second most frequently diagnosed cancer worldwide and represents a major challenge for public health. Despite advances in molecular profiling, important gaps remain in our understanding of tumorigenesis and the regulatory ...
Dario Monaco, Debora Traversa, Eliseo Mattioli, Francesco Alfredo Zito, Grazia Cristiani, Francesca Buono, Sabina Delcuratolo, Tiziana Guarino, Rosamaria Pinto, Antonia Lasorella, Rosanna Lacalamita, Ernesto Picardi, Stefania Tommasi, Simona De Summa   +13 more
doaj   +1 more source

g-Nomic: a new pharmacogenetics interpretation software

, 2019
Ana Sabater,1 Carlos J Ciudad,2 Marc Cendros,1 Denis Dobrokhotov,1 Juan Sabater-Tobella11Department of Information Technology, EUGENOMIC, Barcelona 08012, Spain; 2Department of Biochemistry and Physiology, University of Barcelona, Barcelona 08028 ...
Dobrokhotov D, Cendros M, Sabater A, Ciudad CJ, Sabater-Tobella J   +4 more
core  

Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes, Daniel G. Di Luca, Connie Marras, Erik Boot, Ryan K.C. Yuen, Anthony E. Lang, Anne S. Bassett   +6 more
wiley   +1 more source

Inconsistency in race and ethnic classification in pharmacogenetics studies and its potential clinical implications

Pharmacogenomics and Personalized Medicine, 2019
Frederick Zhang,1 Joseph Finkelstein21Center for Bioinformatics and Data Analytics, Columbia University Irving Medical Center, New York, NY, USA; 2Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY ...
Zhang F, Finkelstein J
doaj  

Plasma Lidocaine Concentrations During Intravenous Lidocaine Infusion Therapy in the Pediatric Population—A Scoping Review

Pediatric Anesthesia, EarlyView.
ABSTRACT Background Intravenous lidocaine therapy (IVLT) is often used in perioperative multimodal analgesia due to its analgesic, anti‐hyperalgesic, and anti‐inflammatory effects. In adults, IVLT doses of 1–2 mg/kg/h produce plasma concentrations of 1–2 μg/mL, within the presumed therapeutic range of 1–5 μg/mL.
McKenna Postles, Amanda Barton, Nicholas West, Gillian Lauder   +3 more
wiley   +1 more source

Pharmacogenetics and the Blood–Brain Barrier: A Whirlwind Tour of Potential Clinical Utility

Future Pharmacology
Genetic factors influence medication response (pharmacogenetics), affecting the pharmacodynamics and pharmacokinetics of many medicaments used in clinical care.
David R. Skvarc, Trang T. T. Truong, Robert M. Lundin, Russell Barnes, Fiona A. Wilkes, Ajeet B. Singh   +5 more
doaj   +1 more source

Pharmacogenetics -- tailoring treatment for the outliers.

, 2009
http://dx.doi.org/10.1056 ...
Lesko, Lawrence J., Woodcock, Janet
core   +1 more source